Related Experiment Video

Updated: Jan 5, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Targeted and novel therapy in advanced gastric cancer

Julie H Selim1, Shagufta Shaheen2, Wei-Chun Sheu3

  • 11School of Pharmacy, Loma Linda University, Loma Linda, CA 92350 USA.

Experimental Hematology & Oncology
|October 22, 2019
PubMed

Insights

New targeted therapies offer improved survival for advanced gastric cancer (GC) patients. Trastuzumab, ramucirumab, and pembrolizumab show promise in various treatment settings for this challenging disease.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Advanced gastric cancer (GC) treatment has seen significant advancements.
  • Targeted therapies are increasingly integrated into systemic treatment regimens.

Purpose of the Study:

  • To review recent clinical trial data on targeted agents for advanced GC.
  • To summarize the current progress in targeted therapy research for advanced GC.

Main Methods:

  • Review of clinical trial data for targeted agents.
  • Analysis of agents including angiogenesis inhibitors, HER2, MET, EGFR, mTOR, claudin-18.2, PD-1, and DNA-targeting drugs.

Main Results:

  • Trastuzumab plus platinum chemotherapy is standard first-line therapy for HER2-overexpressing GC.
  • Ramucirumab with paclitaxel improves overall survival in the second-line setting.
  • Apatinib, nivolumab, ramucirumab, and TAS-102 show single-agent activity in refractory GC.
  • Pembrolizumab demonstrates high response rates in specific GC subtypes (MSI-high, PD-L1 positive).

Conclusions:

  • Targeted agents have significantly expanded treatment options for advanced GC.
  • Specific targeted therapies are now established standards of care in various lines of treatment.
  • Ongoing research continues to refine and introduce novel targeted therapies for advanced GC.
Keywords:
Gastric cancerHuman epidermal growth factor receptor 2Programmed death-1Targeted therapyVascular endothelial growth factor receptor 2

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.1K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
507
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K